Chronic Myeloid Leukemia

Study confirms target of potent chronic leukemia drug

A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) helps confirm that a molecule targeted ...

Dec 19, 2013
popularity not rated yet | comments 0

Battling defiant leukemia cells

Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine.

Oct 07, 2013
popularity 4 / 5 (1) | comments 0

Study yields new strategy against high-risk leukemia

August 29, 2013) St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective ...

Aug 29, 2013
popularity not rated yet | comments 0

Mutations in CSF3R common in CNL, atypical CML

(HealthDay)—In the war against cancer, it looks like matchmaking—between genes and drugs—could be an important tool, according to new research into the genetic underpinnings of two rare forms of leukemia.

May 09, 2013
popularity not rated yet | comments 0

Doctors say cancer drug costs are too high

More than 100 doctors from around the world have signed a letter decrying the high cost of cancer drugs which reach $100,000 per year or more, and calling for pharmaceutical companies to ease prices.

Apr 26, 2013
popularity 5 / 5 (4) | comments 2

Chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, or nilotinib, which have led to dramatically improved survival rates since their introduction in the last decade.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Team reprograms blood cells into blood stem cells in mice

Researchers at Boston Children's Hospital have reprogrammed mature blood cells from mice into blood-forming hematopoietic stem cells (HSCs), using a cocktail of eight genetic switches called transcription factors. The reprogrammed ...